Back to top

LACOG | Genitourinary Cancer Group

Representatives

Dr. Diogo Assed Bastos
Chair
ICESP – Instituto do Câncer do Estado de São Paulo/ Hospital Sírio-Libanês

Dr. Vinícius Carrera
Executive Director
Oncologia D’or, Salvador

Dr. Andrey Soares
Scientific Director
Centro Paulista de Oncologia

Dr. Diogo Rodrigues Rosa
Educational Director
Grupo Oncoclínicas RJ

Dr. Fernando Nunes
Secretary
Clion – Clínica de Oncologia

Steering Committee

Brazil
Dr. Ana Paula Garcia Cardoso
Hospital Israelita Albert Einstein
São Paulo

Dr. Andre Fay
CPO – Hospital São Lucas da PUCRS
Porto Alegre

Dr. Ariel Galapo Kann
Hospital Alemão Oswaldo Cruz
Salvador

Dr. Carlos Dzik
ICESP – Instituto Câncer do Estado de São Paulo
São Paulo

Dr. Daniel Herchenhorn
Oncologia D’Or
São Luiz

Dr. Evanius Wiermann
Instituto de Oncologia do Paraná
Curitiba

Dr. Fábio Affonso Peixoto
Instituto COI de Pesquisa
São Paulo

Dr. Fabio Schutz
BP – Beneficência Portuguesa
São Paulo

Dr. Fernando Maluf
Hospital São José
Rio de Janeiro

Dr. Fernando Sabino
Hospital Santa Lucia
São Paulo

Dr. Francisco Hidelbrando Alves Mota Filho
Santa Casa de Fortaleza
Fortaleza

Dr. Igor Morbeck
Onco-Vida Instituto Especializado de Oncologia
Brasília

Dr. Karine Martins da Trindade
Oncocentro
São Paulo

Dr. Oren Smaletz
Hospital Israelita Albert Einstein
São Paulo

Dr. Silvana Kelly Moncao do Vale
Americas Oncologia- Hospital Paulistano e Hospital Samaritano
São Paulo

Colombia
Dr. Ray Manneh Kopp
Sociedad de Oncología y hematología del Cesar
Valledupar

LACOG | Genitourinary Cancer Group

Ongoing studies

LACOG 0217 – IRONMAN | Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer 

 

LACOG 0218 – Hercules | A phase II trial of pembrolizumab combined with cisplatin-based chemotherapy as first-line systemic therapy in advanced penile cancer

 

LACOG 0415 – APA in Prostate Cancer | Phase II randomized study of Abiraterone acetate plus ADT versus APALUTAMIDE versus Abiraterone and APALUTAMIDE in patients with advanced prostate cancer with non-castrate testosterone levels

 

LACOG 0515 – Testicular Registry | Multicentric database of patients with germ cell tumor with the purpose of clinical and pathological characterization and evaluation of cancer treatment outcomes

 

LACOG 0519 – PEACE III | A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III

 

LACOG 0620 – ExBAT | Extreme Bipolar Androgen Therapy with Darolutamide and Testosterone Cypionate in Patients with Metastatic Castration-Resistant Prostate Cancer (ExBAT trial)

 

LACOG 1518 – Bladder Cancer Registry | Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America: Retrospective and Translational Multicenter Database

 

LACOG 1818 – Prostate Cancer Registry | Survival outcomes in metastatic prostate cancer in the Brazilian population – analysis of individual characteristics and treatment modalities in different national health institutions